{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:03:35Z","timestamp":1790543015070,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1097\/maj.0b013e3181e99c88","type":"journal-article","created":{"date-parts":[[2010,9,8]],"date-time":"2010-09-08T11:18:00Z","timestamp":1283944680000},"page":"253-257","source":"Crossref","is-referenced-by-count":34,"title":["Opportunistic Fungi: A View to the Future"],"prefix":"10.1016","volume":"340","author":[{"given":"Peter G.","family":"Pappas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10408410903241444","article-title":"Epidemiology of invasive mycoses in North America","volume":"36","author":"Pfaller","year":"2010","journal-title":"Crit Rev Microbiol"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0015","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1080\/13693780802354011","article-title":"What is a species in Aspergillus?","volume":"47","author":"Samson","year":"2009","journal-title":"Med Mycol"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0020","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1128\/JCM.01070-09","article-title":"Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network","volume":"47","author":"Balajee","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0025","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1080\/13693780802562092","article-title":"Aspergillus terreus complex","volume":"47","author":"Balajee","year":"2009","journal-title":"Med Mycol"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0030","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/JCM.00854-09","article-title":"Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in TRANSNET","volume":"47","author":"Baddley","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0035","series-title":"Phylogenies from genetic and morphological characters do not support a revision of Gigasporaceae (Glomeromycota) into four families and five genera","author":"Morton","year":"2010"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0040","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/13693780802524506","article-title":"Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases","volume":"47","author":"Rodriguez-Tudela","year":"2009","journal-title":"Med Mycol"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0045","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/13693780802256539","article-title":"Different virulence of the species of the Pseudallescheria boydii complex","volume":"47","author":"Gilgado","year":"2009","journal-title":"Med Mycol"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0050","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1128\/JCM.00808-07","article-title":"Sporothrix brasiliensis, S. globosa, and S. mexicana, three new Sporothrix species of clinical interest","volume":"45","author":"Marimon","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0055","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1128\/JCM.02379-08","article-title":"Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital","volume":"47","author":"Silva","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0060","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.idc.2006.06.009","article-title":"Non-culture-based diagnostics for opportunistic fungi","volume":"20","author":"Mennink-Kersten","year":"2006","journal-title":"Infect Dis Clin North Am"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0065","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1086\/430826","article-title":"Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study","volume":"41","author":"Maertens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0070","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1086\/343804","article-title":"Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients","volume":"186","author":"Maertens","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0075","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S1473-3099(04)01045-X","article-title":"Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis","volume":"4","author":"Mennink-Kersten","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0080","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood.V97.6.1604","article-title":"Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation","volume":"97","author":"Maertens","year":"2001","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0085","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of the EORTC\/MSG Consensus Group for invasive fungal diseases","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0090","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1086\/496927","article-title":"Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study","volume":"41","author":"Maertens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0095","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1086\/382224","article-title":"False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam","volume":"38","author":"Viscoli","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0100","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1086\/421944","article-title":"Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome","volume":"39","author":"Odabasi","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0105","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1086\/432470","article-title":"Multicenter clinical evaluation of the (1\u21923)-beta-D-glucan assay as an aid to diagnosis of fungal infections in humans","volume":"41","author":"Ostrosky-Zeichner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0110","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0115","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1128\/AAC.00658-06","article-title":"Reactivity of (1\u21923)-beta-D-glucan assay with commonly used intravenous antimicrobials","volume":"50","author":"Marty","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0120","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10096-004-1215-4","article-title":"Prophylaxis and treatment of invasive candidiasis in the intensive care setting","volume":"23","author":"Ostrosky-Zeichner","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0125","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10096-007-0270-z","article-title":"Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting","volume":"26","author":"Ostrosky-Zeichner","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.7326\/0003-4819-149-2-200807150-00004","article-title":"Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial","volume":"149","author":"Schuster","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0135","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0140","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1128\/AAC.46.8.2564-2568.2002","article-title":"Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis","volume":"46","author":"Kirkpatrick","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0145","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1086\/375420","article-title":"Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin","volume":"187","author":"Petraitis","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0150","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/423380","article-title":"Combination antifungal therapy for invasive aspergillosis","volume":"39","author":"Marr","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0155","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/01.tp.0000202421.94822.f7","article-title":"Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study","volume":"81","author":"Singh","year":"2006","journal-title":"Transplantation"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0160","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0165","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1056\/NEJM197907193010303","article-title":"A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis","volume":"301","author":"Bennett","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0170","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1056\/NEJM198708063170602","article-title":"Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks","volume":"317","author":"Dismukes","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0175","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0180","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM199707033370103","article-title":"Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome","volume":"337","author":"Van der Horst","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0002870","article-title":"Major role for amphotericin B-flucytosine combination in severe cryptococcosis","volume":"3","author":"Dromer","year":"2008","journal-title":"PLoS One"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0190","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(04)16301-0","article-title":"Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomized trial","volume":"363","author":"Brouwer","year":"2004","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0195","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/QAD.0b013e32832605fe","article-title":"Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures","volume":"23","author":"Bicanic","year":"2009","journal-title":"AIDS"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0200","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1086\/588792","article-title":"High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial","volume":"47","author":"Bicanic","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0205","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1086\/599112","article-title":"A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0210","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/604716","article-title":"Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients","volume":"49","author":"Bicanic","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0215","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10096-008-0466-x","article-title":"Candida infective endocarditis","volume":"27","author":"Baddley","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0220","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/clinids\/6.6.791","article-title":"Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis","volume":"6","author":"Smego","year":"1984","journal-title":"Rev Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0225","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1086\/503428","article-title":"A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis","volume":"42","author":"Pachl","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0230","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0235","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/510677","article-title":"Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts","volume":"44","author":"Segal","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0240","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/374557","article-title":"Voriconazole treatment for less-common, emerging, or refractory fungal infections","volume":"36","author":"Perfect","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0245","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1086\/367933","article-title":"Voriconazole: a new triazole antifungal agent","volume":"36","author":"Johnson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0250","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1345\/aph.1L005","article-title":"Posaconazole: an oral triazole with an extended spectrum of activity","volume":"42","author":"Rachwalski","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0255","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0260","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullman","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0265","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0270","first-page":"165","article-title":"Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole","volume":"11","author":"Pasqualotto","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1097\/MAJ.0b013e3181e99c88_bb0275","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13693780701730469","article-title":"Renal impairment and amphotericin B formulations in patients with invasive fungal infections","volume":"46","author":"Saliba","year":"2008","journal-title":"Med Mycol"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915315068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915315068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T02:59:07Z","timestamp":1636426747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915315068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0002962915315068"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e3181e99c88","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}